Lilly buys migraine antibody

Share this article:

Eli Lilly announced Monday that it scooped up rights for an antibody that Phase-II data indicate may help treat recurrent migraine headaches.

Lilly had in fact discovered the molecule, LY2951742, which is a calcitonin gene-related peptide antibody, but licensed development to Arteaus Therapeutics. The development deal was an alternative risk-sharing strategy: Atlas Venture and Orbimed created Arteaus in 2011 once the antibody license was in place.

Eli Lilly said it expects Monday's deal will trigger a $57.1 million pre-tax fourth-quarter charge.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions